Serum concentration of beta amyloid peptide and the activity of angiotensin converting enzyme in alzheimer's disease patients: search for a potential biomarker


  • Saeed Emadi Department of Biological Sciences, Institute for Advanced Studies in Basic Sciences (IASBS), Zanjan
  • Leila Aghababaee Department of Biological Sciences, Institute for Advanced Studies in Basic Sciences (IASBS), Zanjan
  • Mehdi Maghbooli Department of Neurology, Zanjan University of Medical Sciences, Zanjan



Alzheimer's disease, Blood serum, Beta amyloid peptide, Angiotensin converting enzyme


Background: Alzheimer’s disease (AD) is a disorder that affects mainly aged population. There is still no diagnostic test for the disease. Over the past few years investigators have studied several plasma biomarkers, most frequently, plasma beta amyloid peptide (Aβ). Level of Aβ depends on balance between production and clearance, accomplished by proteases. Our purpose was to study differences in the concentrations of Aβ's (and their ratios) and also in the activity of ACE in blood serum of AD patients and control groups.

Methods: We measured the blood levels of beta amyloid 40 and 42 (Aβ40 & Aβ42) and their proportions in AD patients' blood samples. We also measured the angiotensin converting enzyme (ACE) activities.

Results: This study showed that amounts of Aβ40 and Aβ42 in the blood serum of AD patients were significantly lower than that in control samples. The ratio of Aβ42/Aβ40 was not significantly different from controls. With respect to age and severity of disease we observed that Aβ40 concentration was lower in AD male patients and decreased with severity of AD. We also observed that serum Aβ42 concentration was decreased by increasing the age of female patients.

Conclusions: Our results indicated that the ACE activity was significantly higher in patients in comparison with normal individuals. Also, it was revealed that increase in age resulted in reduced ACE activity in females and increased activity in males. This study also showed there was a positive relationship between ACE activity and severity of disease.


Seshadri S, Beiser A, Kelly-Hayes MRN, Kase CS, Au R, Kannel WB. The lifetime risk of stroke: Estimates from the Framingham Study. Stroke. 2006;37:345-50.

Hanger DP, Pooler AM, Noble W. A role for tau at the synapse in Alzheimer’s disease pathogenesis. Neuropharmacology. 2014;76:1-8.

Morris AM, Watzky MA, Finke RG. Protein aggregation kinetics, mechanism, and curve-fitting. Biochim Biophys Acta. 2009;1794:375-97.

Rosenblum WI. Why Alzheimer trials fail: Removing soluble oligomeric beta amyloid is essential, inconsistent, and difficult. Neurobiol Aging. 2014;35:969-74.

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease. Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34:939-44.

Gauthier S, Leuzy A, Racine E, Rosa-Neto P. Diagnosis and management of Alzheimer’s disease: Past, present and future ethical issues. Prog Neurobiol. 2013;110102-113.

Teipel SJ, Grothe M, Lista S, Toschi N, Garaci FG, Hampel H. Relevance of magnetic resonance imaging for early detection and diagnosis of Alzheimer disease. Med Clin N Am. 2013;97:399-424.

Blennow K, Zetterberg H. The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease. Med Clin N Am. 2013;97:369-76.

Lista S, Garaci FG, Ewers M, Teipel S, Zetterberg H, Blennow K. CSF Aβ1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer’s disease. Alzheimers Dement. 2014;10:381-92.

Molinuevo JL , Blennow K, Dubois B, Engelborghs S, Lewczuk P, Perret-Liaudet A. The clinical use of cerebrospinal fluid biomarker testing for Alzheimer’s disease diagnosis: A consensus paper from the Alzheimer’s Biomarkers Standardization Initiative. Alzheimers Dement. 2014;10:808-17.

Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D. Isolation and quantification of soluble Alzheimer’s beta-peptide from biological fluids. Nature. 1992;359:325-7.

Cappai R, White AR. Amyloid beta. Int J Biochem Cell Biol. 1999;31:885-9.

Masters CL, Cappai R, Barnham KJ, Villemagne VL. Molecular mechanisms for Alzheimer’s disease: Implications for neuroimaging and therapeutics. J Neurochem. 2006;97:1700-25.

Cummings JL. Biomarkers in Alzheimer's disease drug development. Alzheimers Dement. 2011;7:13-44.

Rogeberg M, Furlund CB, Moe MK, Fladby T. Identification of peptide products from enzymatic degradation of amyloid beta. Biochimie. 2014;105:216-20.

Wang YJ, Zhou HD, Zhou XF. Clearance of amyloid-beta in Alzheimer’s disease: Progress, problems and perspectives. Drug Discov Today. 2006;11:931-8.

Qosa H, Abuasal BS, Romero IA, Weksler B, Couraud P-O, Keller JN. Differences in amyloid-β clearance across mouse and human blood-brain barrier models: Kinetic analysis and mechanistic modeling. Neuropharmacology. 2014;79;668-78.

Koyama A, Okereke OI, Yang T, Blacker D, Selkoe, DJ, Grodstein, F. Plasma amyloid-β as a predictor of dementia and cognitive decline: A systematic review and meta-analysis. Arch Neurol. 2012;69:824-31.

Liu Y, Qing H, Deng Y. Biomarkers in Alzheimer’s disease analysis by mass spectrometry-based proteomics. Int J Mol Sci. 2014;15:7865-82.

Mayeux R, Schupf N. Blood-based biomarkers for Alzheimer’s disease: Plasma Aβ40 and Aβ42 and genetic variants. Neurobiol Aging. 2011;32:10-9.

Rembach A, Faux NG, Watt AD, Pertile KK, Rumble RL, Trounson BO. Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer’s disease. Alzheimers Dement. 2014;10:53-61.

Fukumoto H, Tennis M, Locascio JJ, Hyman, BT, Growdon, JH, Irizarry MC. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol. 2003;60:958-64.

Sedaghat F, Dedousic E, Costa V, Dimitriadis AS, Baloyannis SJ. Plasma levels of amyloid beta 1-42 are independent of neuronal function in Alzheimer’s disease. J Alzheimers Dis. 2009;17:343-8.

Assini A, Cammarata S, Vitali A, Colucci M, Giliberto L, Borghi R. Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment. Neurology. 2004;63:828-31.

Sobów T, Flirski M, Kłoszewska I, Liberski PP. Plasma levels of alpha beta peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer’s disease. Acta Neurobiol Exp. 2005;65:117-24.

Mehta PD, Pirttilä T, Mehta SP, Sersen EA, Aisen PS, Henryk M. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol. 2000;57:100-5.

Le Bastard N, Leurs J, Blomme W, De Deyn PP, Engelborghs S. Plasma amyloid-beta forms in Alzheimer’s disease and non-Alzheimer’s disease patients. J Alzheimers Dis. 2010;21:291-301.

Pesaresi M, Lovati C, Bertora P, Mailland E, Galimberti D, Scarpini E. Plasma levels of beta-amyloid (1-42) in Alzheimer’s disease and mild cognitive impairment. Neurobiol Aging. 2006;27:904-5.

Lewczuk P, Kornhuber J, Vanmechelen E, Peters O, Heuser I, Maier W. Amyloid beta peptides in plasma in early diagnosis of Alzheimer’s disease: A multicenter study with multiplexing. Exp Neurol. 2010;223:366-70.

Lui JK, Laws SM, Li Q-X, Villemagnec VL, Ames D, Browna B. Plasma amyloid-beta as a biomarker in Alzheimer’s disease: The AIBL study of aging. J Alzheimers Dis. 2010;20:1233-42.

Hana Y, Jia J, Jia X-F, Qin W, Wang S. Combination of plasma biomarkers and clinical data for the detection of sporadic Alzheimer’s disease. Neurosci Lett. 2014;516:232-6.

Mayeux R, Honig LS, Tang M-X, Manly J, Stern Y, Schupf N. Plasma Aβ40 and Aβ42 and Alzheimer’s disease: Relation to age, mortality, and risk. Neurology. 2003;61:1185-90.

Schupf N, Tang MX, Fukuyama H, Manly J, Andrews H, Mehta P. Peripheral Aβ subspecies as risk biomarkers of Alzheimer’s disease. Proc Natl Acad Sci USA. 2008;105:14052-7.

Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E. Evaluation of plasma Aβ(40) and Aβ(42) as predictors of conversion to Alzheimer’s disease in patients with mild cognitive impairment. Neurobiol Aging. 2010;31:357-67.

Hemming ML, Selkoe DJ. Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem. 2005;280:37644-50.

Chapman MR, Hammer ND, Wang X, McGuffie BA. Amyloids: Friend or Foe? J Alzheimers Dis. 2008;13:407-19.

Akatsu H, Ogawa N, Kanesaka T, Hori A, Yamamoto T, Matsukawa N. Higher activity of peripheral blood angiotensin-converting enzyme is associated with later-onset of Alzheimer's disease. J Neurol Sci. 2011;300:67-73.

Raber J, Huang Y, Ashford JW. ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol Aging. 2004;25:641-50.

Mooradian AD, Lieberman J. Age-related decrease in serum angiotensin converting enzyme activity: The role of thyroidal status and food intake. J Gerontol. 1990;45:24-7.

Zou K, Yamaguchi H, Akatsu H, Sakamoto T, Ko M, Mizoguchi K. Angiotensin converting enzyme converts amyloid beta-protein 1–42 (Aβ (1–42)) to Aβ (1–40), and its inhibition enhances brain Aβ deposition. J Neurosci. 2007;27:8628-35.

Miners S, Ashby E, Baig S, Harrison R, Tayler H, Speedy E. Angiotensin converting enzyme levels and activity in Alzheimer’s disease: Differences in brain and CSF ACE and association with ACE1 genotypes. Am J Transl Res. 2009;1:163-77.

Jochemsen HM, Teunissen CE, Ashby EL, van der Flier WM, Jones RE, Geerlings MI. The association of angiotensin-converting enzyme with biomarkers for Alzheimer’s disease. Alzheimers Res Ther. 2014;6:27.

Vardy ER, Rice PJ, Bowie PC, Holmes JD, Catto AJ, Hooper NM. Plasma angiotensin-converting enzyme in Alzheimer’s disease. J Alzheimers Dis. 2009;16:609-18.

Paul LH, Chris S. Optimized assay for serum angiotensin-converting enzyme activity. Clin Chem. 1981;27:2048-52.

Barnes NM, Cheng CHK, Costall B, Naylor RJ, Williams TJ, Wischik CM. Angiotensin converting enzyme density is increased in temporal cortex from patients with Alzheimer's disease. Eur J Pharmacol. 1991;200:289-92.

Savaskan E, Hock C, Olivieri G, Bruttel S, Rosenberg C, Hulette C. Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer's dementia. Neurobiol Aging. 2001;22:541-6.

Miners JS, Ashby E, Van Helmond Z, Chalmers KA, Palmer LE, Love S. Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer's disease, and relationship of perivascular ACE-1 to cerebral amyloid angiopathy. Neuropathol Appl Neurobiol. 2008;34:181-93.

Elkins JS, Douglas VC, Johnston SC. Alzheimer disease risk and genetic variation in ACE: A meta-analysis. Neurology. 2004;62:363-8.




How to Cite

Emadi, S., Aghababaee, L., & Maghbooli, M. (2016). Serum concentration of beta amyloid peptide and the activity of angiotensin converting enzyme in alzheimer’s disease patients: search for a potential biomarker. International Journal of Research in Medical Sciences, 4(2), 421–427.



Original Research Articles